In the last trading session, 5.55 million AbCellera Biologics Inc (NASDAQ:ABCL) shares changed hands as the company’s beta touched 0.42. With the company’s per share price at $2.82 changed hands at -$0.17 or -5.69% during last session, the market valuation stood at $832.94M. ABCL’s last price was a discount, traded about -86.52% off its 52-week high of $5.26. The share price had its 52-week low at $2.34, which suggests the last value was 17.02% up since then.
Analysts gave the AbCellera Biologics Inc (ABCL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ABCL as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. AbCellera Biologics Inc’s EPS for the current quarter is expected to be -0.15.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Instantly ABCL was in red as seen at the end of in last trading. With action -17.78%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -3.75%, with the 5-day performance at -17.78% in the red. However, in the 30-day time frame, AbCellera Biologics Inc (NASDAQ:ABCL) is -18.97% down.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 43.6% from its current market value. According to analyst projections, ABCL’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -77.3% plunge from its current level, while the stock would need to soar -77.3% for it to hit the projected low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Year-over-year growth is forecast to reach -16.95% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 7.58M. 2 analysts are of the opinion that AbCellera Biologics Inc’s revenue for the current quarter will be 13.97M. The company’s revenue for the corresponding quarters a year ago was 9.2M and 9.95M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -17.62%. The estimates for the next quarter sales put growth at 40.33%.
The 2025 estimates are for AbCellera Biologics Inc earnings to decrease by -15.13%, but the outlook for the next 5-year period is at 1.59% per year.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next quarterly earnings report in March.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 7.4472% or 21.91 million shares worth $64.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Biotechnology ETF and Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd . With 1.42 shares estimated at $3.99 million under it, the former controlled 0.48% of total outstanding shares. On the other hand, Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd held about 0.15% of the shares, roughly 454.44 shares worth around $1.28 million.
